@entity157 ( @entity157 ) ranks in prevalence and mortality among top 10 @entity5 worldwide. @entity4877 (BA), a member of histone deacetylase inhibitors (HDACi) has been proposed as an anticarcinogenic agent. However, its short half-life is a therapeutical limitation. This problem could be circumvented with @entity18039 (TB), a proposed BA prodrug. To investigate TB effectiveness for chemoprevention, @entity35 were treated with the compound during initial phases of "resistant hepatocyte" model of hepatocarcinogenesis, and cellular and molecular parameters were evaluated. TB inhibited (p < 0.05) development of @entity99 (PNL) including persistent ones considered @entity157 progression sites. TB increased (p < 0.05) PNL remodeling, a process whereby they tend to disappear. TB did not inhibit cell proliferation in PNL, but induced (p < 0.05) apoptosis in remodeling ones. Compared to controls, @entity35 treated with TB presented increased (p < 0.05) hepatic levels of BA indicating its effectiveness as a prodrug. Molecular mechanisms of TB-induced hepatocarcinogenesis chemoprevention were investigated. TB increased (p < 0.05) hepatic nuclear histone H3K9 hyperacetylation specifically in PNL and @entity7504 protein expression, which could be associated with inhibitory HDAC effects. Moreover, it reduced (p < 0.05) the frequency of persistent PNL with aberrant cytoplasmic @entity10740 accumulation, an alteration associated with @entity5 . Original data observed in our study support the effectiveness of TB as a prodrug of BA and as an HDACi in hepatocarcinogenesis chemoprevention. Besides histone acetylation and @entity7504 restored expression, molecular mechanisms involved with TB anticarcinogenic actions could also be related to modulation of @entity10740 pathways.

Chemoprevention of XXXX hepatocarcinogenesis with histone deacetylase inhibitors: efficacy of @entity18039 , a @entity4877 prodrug.

@entity10740 :: ('301300(Tax:10116)', 'Gene') :: ['p53'] @entity7504 :: ('24525(Tax:10116)', 'Gene') :: ['p21'] @entity5 :: ('MESH:D009369', 'Disease') :: ['increased malignancy', 'cancers'] @entity4877 :: ('MESH:D020148', 'Chemical') :: ['Butyric acid'] @entity18039 :: ('MESH:C005830', 'Chemical') :: ['tributyrin'] @entity35 :: ('10116', 'Species') :: ['rats'] @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'Hepatocellular carcinoma'] @entity99 :: ('MESH:D056486', 'Disease') :: ['hepatic preneoplastic lesions']
@entity35 :: (10116,Species) :: ['rat']
